Trial · NCT06047080
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) as determined by Independent Review Facility (IRF) | From randomization to the first occurrence of disease progression or relapse, or death due to any cause, whichever occurs first (up to approximately 65 months) | |
| Secondary | PFS as determined by the investigator | From randomization to the first occurrence of disease progression or relapse or death from any cause, whichever occurs first (up to approximately 65 months) | |
| Secondary | PFS as determined by the investigator and IRF for participants with international prognostic index (IPI) 3-5 | From randomization to the first occurrence of disease progression or relapse or death from any cause, whichever occurs first (up to 65 months) | |
| Secondary | Event-free survival efficacy causes (EFSeff) | From randomization to the earliest occurrence of disease progression or relapse; death due to any cause; initiation of new anti-lymphoma treatment; or positive biopsy for residual disease after treatment completion (up to approximately 65 months) | |
| Secondary | Complete response (CR) rate | At the end of treatment (up to approximately 65 months) | |
| Secondary | Objective response rate (ORR) | At treatment completion or discontinuation (up to approximately 65 months) | |
| Secondary | Overall survival (OS) | From randomization to death from any cause (up to approximately 65 months) | |
| Secondary | Duration of response (DOR) | From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 65 months) | |
| Secondary | Duration of complete response (DOCR) | From the first occurrence of a documented complete response (CR) to disease progression or death, whichever occurs first (up to approximately 65 months) | |
| Secondary | Disease-free survival (DFS) | From a documented CR at the end of treatment to disease progression or death, whichever occurs first (up to approximately 65 months) | |
| Secondary | Serum concentration of glofitamab | Up to approximately 65 months | |
| Secondary | Incidence of anti-drug antibodies (ADAs) | Baseline up to approximately 65 months | |
| Secondary | Proportion of participants experiencing a clinically meaningful improvement in physical functioning and fatigue (EORTC QLQ-C30) and lymphoma symptoms (FACT-Lym LymS) | Up to approximately 65 months | |
| Secondary | Time to deterioration in physical functioning and fatigue (EORTC QLQ-C30) and lymphoma symptoms (FACT-Lym LymS) | Up to approximately 65 months | |
| Secondary | Percentage of Participants with Adverse Events (AEs) | From randomization to the end of study (up to approximately 65 months) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06047080/registered